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Abstract: I n t r o d u c t i o n: Coronary disease is one of the strongest risk factors of developing heart 
failure. Identifi cation of the predictive factors of left  ventricle (LV) function deterioration in patients with 
stable angina pectoris and normal systolic function of LV, is a challenge for clinicians.
O b j e c t i v e: Identification of prognostic factors: clinical, echocardiographic, biochemi-
cal (NT-proBNP, hsCRP) and spiroergometric of left  ventricle function deterioration in patients 
with coronary disease and normal results of baseline echocardiographic examination in a  2-year 
observation.
P a t i e n t s  a n d  m e t h o d s: Th e study group comprised of 32 patients with stable angina pectoris 
and normal heart function, aged 50.9 ± 4 years; 23 men (71.8%). At baseline we performed echocardi-
ography, cardiopulmonary exercise testing and determined serum levels of B-type natriuretic peptide 
and C-reactive protein. 24 months later we performed echocardiography and cardiopulmonary exercise 
testing. 
R e s u l t s: Patients with stable angina pectoris and normal LV function are at risk of developing the 
impairment of LV function. Diastolic dysfunctions of LV are a  crucial element of the whole clinical 
picture. 53.1% developed of LV diastolic dysfunction: 37% isovolumetric relaxation disorders and 15% 
pseudonormalization. Th e analysis of the tests carried out aft er a 2-year observation indicated a relation-
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ship between developing diastolic dysfunction of LV and the presence of type II diabetes (p = 0.01). Peak 
oxygen consumption (VO2peak) at baseline was signifi cantly lower in patients who developed diastolic 
dysfunction of LV aft er 2 years (p = 0.03).
C o n c l u s i o n s: Th e predictors of LV diastolic function deterioration in a 2-year observation in this 
group of patients include type II diabetes and peak oxygen consumption VO2peak.
Key words: dysfunction of left  ventricle, patients with stable angina pectoris, prognostic factors of left  
ventricle dysfunction.
Introduction
Coronary disease is one of the strongest risk factors of developing heart failure [1]. 
Diagnosing cardiac dysfunction in the asymptomatic stages allows to implement ear-
ly treatment and impede the progression of heart muscle dysfunction [2]. Asymp-
tomatic impairment of left  ventricle function develops in approximately 62% of 
adults [3–6]. 
According to a number of studies, increased NT-proBNP (N-terminal-pro B-type 
Natriuretic Peptide) plays a crucial role in the detection of left  ventricle dysfunction 
[7, 8]. Few reports indicated that the analysis of CRP concentration and its altered 
level in time allows to predict the progression of heart failure and establish the 
prognosis [9]. Th is refers to considerably low CRP values (3–10 mg/L) [10]. Th erefore, 
reliable high sensitivity tests for CRP (hsCRP) have been compiled [10].
Identifi cation of the predictive factors of heart function deterioration in the group 
of patients with increased risk of developing heart failure, including patients with 
stable angina pectoris and normal systolic function of left  ventricle, is a  challenge 
for clinicians. It will allow to select patients requiring more frequent check-ups and 
modifi cation of pharmacological treatment to prevent or delay the development of 
clinically evident heart failure. Th e study involved an attempt to establish factors 
determining left ventricle function deterioration in patients with stable angina 
pectoris without left  ventricle dysfunction. 
Objective
Identifi cation of prognostic factors: clinical, echocardiographic, biochemical (NT-
proBNP, hsCRP) and spiroergometric of left  ventricle function deterioration in pa-
tients with coronary disease and normal results of baseline echocardiographic exami-
nation in a 2-year observation.
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Patients and methods
Th e study group comprised 32 patients with coronary disease and normal heart func-
tion hospitalized in the Department of Coronary Disease, John Paul II Specialist Hos-
pital in Krakow, aged from 39 to 55 years (mean 50.9 ± 4 years). Men constituted 
71.8% of the group (n = 23). 
Inclusion cr iter ia were: age between 30 and 60 years, diagnosed coronary 
disease confi rmed with coronarography or exertion scintigraphy, good conditions for 
echocardiographic examination and patient’s consent for the test. 
Exclus ion cr iter ia  were: clinical signs of heart failure, impaired function 
of left  ventricle, past myocardial infarction, evident signs of heart failure, valvular 
defects, cardiomyopathy, unsuccessful normalization of arterial pressure within 
2 previous years, organ changes in course of diabetes, renal failure, thyroid disorders, 
cancer, liver diseases considerably impairing its function and pregnancy. 
Th e following were analyzed both at baseline and aft er 2 years of observation: 
clinical status (interview with the evaluation of the severity of angina pectoris 
and physical examination, presence of atherosclerotic risk factors), rest 12-lead 
electrocardiogram, resting transthoracic echocardiogram and the results of 
spiroergometric test. On inclusion to the study, the concentrations of NT-proBNP and 
CRP in the serum were tested. At that point patients were treated pharmacologically 
according to recommendations. Laboratory tests were performed in the laboratory in 
John Paul II Specialist Hospital in Kraków. Th e protocol of the study was approved by 
the Bioethics Committee of the Jagiellonian University in Kraków (KBET/7B/2005). 
The patients were tested for changes in systolic and diastolic heart function 
aft er 2 years. Th e study included the identifi cation of prognostic factors in a  2-year 
observation: clinical factors, particular echocardiographic and spiroergometric 
parameters and NT-proBNP.
Transthoracic resting echocardiogram
Standard views were analyzed: parasternal long axis, parasternal short axis, four-
chamber view and two-chamber view. Also, local speed of mitral annulus movement 
was evaluated with the use of spectrum technique of tissue testing with Doppler 
method (TDE/DTI). Th e infl ow profi le in pulmonary veins and local speed of mitral 
annulus movement were examined with Doppler tissue method. 
Th e volume of left  ventricle and ejection fraction were measured with biplane 
Simpson’s method. End-diastolic parameters were measured in the picture registered 
on the peak R wave of QRS complex in ECG. Measurements of each parasternal and 
apical view were carried out. Statistical analysis included approximate values of those 
measurements. 
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Th e analysis included the following non-invasive indicators of increased end-
diastolic pressure: ratio of early mitral fl ow velocity to mitral annulus movement in 
TDI (E/E’) as well as the ratio of maximal velocity of early mitral infl ow to the velocity 
of early infl ow propagation (E/Vp). Th e measurements were carried out according to 
the guidelines of American Echocardiographic Society. 
Th e profi le of left  ventricular mitral infl ow was evaluated based on diagnostic 
criteria of diastolic failure by the European Cardiology Society and the classifi cation 
of the Canadian Cardiology Society. 
Spiroergometric test result
Spiroergometric tests were carried out according to the modifi ed Bruce’s protocol 
with the use of treadmill. Th e following parameters were analyzed: VO2 max, VCO2, AT 
and VE/VCO2. 
Also, the analysis of developing systolic and diastolic dysfunction of left  ventricle 
was performed as well as the relationship between the following echocardiographic, 
spiroergometric and biochemical parameters: hemodynamic state marker NT-proBNP 
and CRP infl ammatory marker was examined. 
Based on the outcomes of echocardiographic tests — baseline (E1) and after 
2 years (E2), the evaluation of changes in the baseline LV fi lling profi le and systolic 
function in terms of trends in changes in the LV fi lling profi le and systolic function in 
time interval between E1 and E2 tests was carried out.
Next, the relationship between the trends in changes in LV fi lling profi le and 
age, accompanying disorders and particular echocardiographic and biochemical 
parameters was analyzed in order to determine prognostic factors of LV systolic and 
diastolic function deterioration. Certain outcomes of this analysis had been previously 
presented in two publications [11, 12].
Statistical anal ysis
Statistical analysis was performed with STATISTICA 8 statistical soft ware by 
StatSoft  Inc. (2008). Th e obtained data were presented in form of tables including 
distribution parameters: x — arithmetic mean, SD — standard deviation, min — 
minimal value and max — maximal value. Th e charts present comparisons of test 
outcomes. 
Th e following methods were applied in the statistical analysis:
t-Student test for independent tests in comparison with quantity variables and 
for repetitive tests in the comparison of 2 groups, multifactor variance analysis 
(ANOVA) to examine the relationship of systolic function, mitral infl ow profi le and 
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spiroergometric test parameters with the analyzed quantity variables and for repetitive 
tests in case of comparing 2 subsequent tests, Chi2 independence test to analyze the 
relationship between mitral infl ow profi le and the analyzed quality variables. 
Test results with significance less or equal 0.05 (p ≤0.05) were considered 
statistically signifi cant.
Results
General characteristics of patients
Th e study group consisted of 32 patients with coronary disease and normal LV systolic 
and diastolic function aged from 39 to 55 years (mean 50.9 ± 4 years). Men constituted 
71.8% of the group (n = 23). 
Arterial hypertension was found in 29 (90%) patients, lipid disorders in 23 
individuals (71.8%) while type II diabetes in 6 patients (0.19%). Metabolic syndrome 
was diagnosed in 4 individuals (12.5%), addiction to tobacco was found in 18 patients 
(56%) while contributory family history in 21 patients (66%). Mean body mass index 
was 28.17 ± 4.4 kg/m2. Pain symptoms related to coronary disease class II according 
to CCS were found in 53% of patients, class I in 43% of patients while class III only 
in one individual. 
Tables 1 and 2 present clinical characteristics of the patients including atheroscle-
rosis risk factors.
Table 1. Characteristics of the patients.
Examined parameters Male n (%) Age (years)x ± SD
BMI (kg/m2)
x ± SD
Examined group n = 32 23 (71.8%) 50.9 ± 4 28.17 ± 4.4
Data are expressed as mean ± standard deviation.
Abbreviations: BMI — body mass index.
Table 2. Atherosclerosis risk factors in the examined patients.
Risk factors of 
atherosclerosis
Arterial 
hypertension
n (%)
Diabetes
type 2
n (%)
Smoking
n (%)
Hypercholestero-
laemia
n (%)
Metabolic
syndrome
n (%)
CAD 
in family 
history
Examinated group 
n = 32 29 (90%) 6 (18.7%) 18 (56%) 23 (71.8%) 4 (12.5%) 21 (66%)
Abbreviations: CAD — Coronary Artery Disease. 
Table 3 presents echocardiographic parameters in the examined patients.
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Table 3. Echocardiographic parameters in the examined patients.
Echocardiographic 
parameters x ± SD
EF (%) 62.00 ± 5.3
DT (ms) 207.90 ± 47.0
E/A 1.18 ± 0.3
E/E’ 3.40 ± 0.8
E/Vp 1.26 ± 0.3
Vp (cm/s) 65.00 ± 20.0
LA (mm) 36.50 ± 3.8
LA area (cm2) 17.60 ± 2.3
LVEDD (mm) 50.70 ± 5.6
LVMAS (g) 190.80 ± 62.6
LVMI (g/m2) 96.80 ± 30.8
Abbreviations: A — the peak late mitral fl ow velocity, DT — deceleration time, E — the peak early mitral fl ow 
velocity, E’ — the peak early diastolic myocardial tissue velocity, EF — ejection fraction, LA — left  atrium, 
LAarea — left  atrial area, LVEDD — left  ventricle end-diastolic diameter, LVMAS — left  ventricle mass, 
LVMI — left  ventricle mass index, Vp — early diastolic fl ow propagation velocity.
Biochemical tests
NT-proBNP in the examined group ranged from 8.928 to 155.4 pg/ml, mean 
49.26 ± 35.4 pg/ml. High sensitivity C-reactive protein values (hsCRP) ranged from 
0.45 to 20.31 mg/l, mean 3.13 ± 3.92 mg/l. 
Table 4. NT-proBNP values in the examined group and hsCRP.
Examined marker x SD min max p
NT-proBNP (pg/ml) 49.3 35.4 8.90 155.4 NS
hsCRP (mg/l)  4.4  8.5 0.45  45.8 NS
Abbreviations: hsCRP — high-sensitivity, C — Reactive Protein, NT-proBNP — N-terminal-proB-type Natriuretic 
Peptide.
Results of baseline spiroergometric test are presented in Table 5.
In patients at baseline peak oxygen (V02 peak) uptake was 18.8–42.4 ml/kg/min, 
mean 28.8 ± 6.0 ml/kg/min. Th e volume of CO2 ranged between 0.64 do 3.4 l/min, 
mean 2.09 ± 0.76 l/min. Anaerobic threshold ranged between 15 and 23 ml/kg/min, 
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Table 5. Results of spiroergometric test at baseline in the examined group. 
Spiroergometric parameters Examinated patientsx ± SD
Patients with diabetes type 2
x ± SD
VO2 peak (ml/kg/min) 28.80 ± 6.00 25.8 ± 3.0
VCO2 (l/min) 2.09 ± 0.76 2.3 ± 0.7
AT 18.00 ± 2.50 13.0 ± 3.0
VE/VCO2 28.80 ± 4.90 30.0 ± 3.0
VE max 67.90 ± 20.00 74.7 ± 20.0
HR peak exercise (n/min) 131.00 ± 19.00 134.5 ± 18.3
Abbreviations: AT — anaerobic threshold, HR — heart rate, VE — ventilatory equivalent, VE/VCO2 — ventilatory 
equivalent of carbon dioxide, VO2 peak — oxygen uptake at the peak exercise.
mean 18 ± 2.5 ml/kg/min. Maximal ventilation was from 36.1 to 102.4, mean 
67.9 ± 20  ml/min. Ventilatory equivalent of CO2 ranged from 24 to 44, mean 
28.8 ± 4.9. Respiratory quotient was 0.72–1.26, mean 0.99 ± 0.13. Peak exercise heart 
rate was 90–168, mean 131 ± 19 beats per minute.
Changes in the function of LV in patients in a 2-year observation
According to the analysis of LV function changes, LV systolic and diastolic function 
remained unchanged in 15 individuals (46.9%) out of 32 patients. 17 patients (53.1%) 
developed disorders of LV diastolic function: isovolumetric relaxation disorders in 
12 patients (37%) and pseudonormalization in 5 patients (15%). 
Prognostic factors of LV fi lling profi le deterioration in patients with stable 
angina and normal heart function in a 2-year observation
Th e comparison of test results performed at baseline and aft er a  2-year observation 
are presented in Table 6. 
Table 6. Comparison of signifi cantly diff erent parameters of spiroergometric tests in patients with and 
without LV function deterioration aft er 2 years. 
Spiroergometric 
parameters
x ± SD
Examinated group
pwithout deteriorating LV function
n = 15
with deteriorating LV function
n = 17
VO2 peak 1 (ml/kg/min) 31.3 ± 6.6 26.7 ± 4.5 0.03
VO2 peak 2 (ml/kg/min) 31 ± 6.3 24.8 ± 6 0.03
Abbreviations: LV — left  ventricle, VO2 peak — oxygen uptake at the peak exercise.
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Peak oxygen consumption (VO2 peak) at baseline was signifi cantly lower in the 
group with diastolic dysfunction compared to patients with normal function of left  
ventricle and ranged between to 18.8 and 31.7, mean 26.7 ± 4.5 ml/kg/min (p = 0.03). 
Th ese results has been presented previously [12]. 
The analysis of the tests carried out after a  2-year observation indicated 
a  relationship between developing diastolic dysfunction and the presence of type  II 
diabetes (p = 0.01). Diastolic dysfunction of LV occurred in all patients with type  2 
diabetes aft er a  2-year observation: isovolumetric relaxation disorders developed in 
4 patients and pseudonormalization in 2 patients. Table 7 presents echocardiographic 
parameters in patients with diabetes type 2 assessed at the start of the trial and aft er 
2 years.
Table 7. Echocardiographic parameters in patients with diabetes type 2 in fi rst examination and aft er 
2 years.
Echocardiographic parameters
x ± SD
Examinated patients 
with diabetes type 2
In the 1st Echo
Examinated patients 
with diabetes type 2
Aft er 2 years
EF (%) 63.00 ± 4.40 66.00 ± 7.50
DT (ms) 203.00 ± 31.40 265.20 ± 41.60
E/A 1.26 ± 1.36 0.54 ± 0.17
E/E’ 4.00 ± 1.09 6.30 ± 4.10
E/Vp 1.24 ± 0.27 1.47 ± 0.46
Vp (cm/s) 63.00 ± 9.70 43.60 ± 18.15
LV mass/BSA(g/m2) 98.70 ± 27.00 111.40 ± 43.40
Abbreviations: BSA — body surface area, LVMI — left  ventricle, others — see Table 3.
No significant relationship between diastolic function deterioration and age 
(p = 0.56), arterial hypertension (p = 0.27), addiction to smoking cigarettes (0.7), lipid 
disorders (p = 0.86) BMI (p = 0.2) or positive family history (p = 0.5) was observed.
No signifi cant relationship between LV function deterioration aft er 2 years and 
the baseline level of NT-proBNP or hsCRP was found. Table 8 presents baseline 
NT-proBNP and hsCRP values in patients whose LV function remained unchanged 
and those with LV function deterioration.
According to the analysis of spiroergometric parameters aft er a 2-year observation, 
there is a relationship between VO2 peak 2 and a change in normal profi le of left  ventricle 
fi lling and impaired fi lling (p = 0.015). No such relationship in case of other analyzed 
parameters of spiroergometric test was found: AT2 (p = 0.6), VE/CO2 peak 2 (p = 0.22) 
and RQ2 (p = 0.6), as described in the previous publication [12].
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Table 8. Biochemical tests in patients with and without deterioration of LV function.
Biochemical marker
Group A
p
without LV function deteriorating with LV function deteriorating
NT-proBNP 43.9 ± 32.9 53.90 ± 37.80 NS
hsCRP 2.0 ± 1.8  6.56 ± 11.28 NS
Abbreviations: hsCRP — high-sensitivity, C — Reactive Protein, NT-proBNP — N-terminal-proB-type Natriuretic 
Peptide.
Discussion
Coronary disease, as an etiologic factor, is related to poor prognosis in patients with 
heart failure [13, 14]. Early latent stage of the disease ought to be taken into consid-
eration in the natural course of heart failure development since it is crucial for the 
implementation of screening test program in groups of patients at risk of develop-
ing a  full-blown heart failure [15]. Th e outcomes of own study as well as research by 
other authors prove that patients with stable angina pectoris without impaired heart 
function are highly at risk of developing heart failure. Diastolic dysfunction of left  
ventricle is a crucial element of the whole clinical picture in these patients. 
Literature reports emphasize the role of the following factors predisposing to 
the development of heart failure: older age, female gender, diabetes, obesity, arterial 
hypertension and the enlargement of left  ventricle [16]. According to this study, type II 
diabetes in patients with normal heart function at baseline signifi cantly infl uenced the 
deterioration of left  ventricle diastolic function in a 2-year observation (p = 0.01). Th is 
is related to an unfavorable impact of metabolic disturbances on vascular walls and 
heart muscle. Both own research and literature data indicate that patients with stable 
angina pectoris and the accompanying type II diabetes ought to periodically undergo 
control echocardiographic examination to assess early impairment of left  ventricle 
function [17].
Prognostic values of the analyzed echocardiographic, biochemical and spiro-
ergometric parameters in a 2-year observation in patients with stable angina pectoris 
and normal LV function were determined. 
Echocardiography is considered the best method to detect asymptomatic 
heart dysfunction [18]. According to current guidelines, Doppler two-dimension 
echocardiography is a  test of the highest prognostic value [19]. The study also 
included the analysis of echocardiography results in the aspect of the development of 
left  ventricle dysfunction.
Patients with angina and normal LV function are at risk of developing LV diastolic 
dysfunction despite the treatment. Th e profi le of disturbed relaxation is a  common 
type of left  ventricle diastolic dysfunction in these individuals. 
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Th is work included the analysis of the parameters of spireorgometric test which is 
a gold standard in the assessment of physical fi tness [20]. 
Th e impairment of heart function involves numerous changes in neurohormonal 
system which are compensation mechanisms. Th ey lead to balancing the decreased 
cardiac output and stroke volume. Initial compensation mechanisms (activation 
of renin-angiotensin-aldosterone system, stimulation of vasopressin production, 
increased sympathetic activation) stop working aft er a  while and give undesirable 
eff ects — blood vessel constriction and heart dilation. Increased pressure in heart 
chambers leads to increased activity of the natriuretic and vasodilating substances 
(e.g. NT-proBNP). Th is balance may be disturbed at physical exertion, which can 
cause circulatory system decompensation. According to literature, both peak oxygen 
consumption and increased respiratory response to exertion are acknowledged 
prognostic parameters [21, 22]. 
Th is work indicated that baseline peak oxygen consumption (VO2 peak) in patients 
without LV dysfunction was signifi cantly lower in the individuals who aft er 2 years 
developed diastolic dysfunction compared to the patients whose left  ventricle function 
remained normal (26.7 ± 4.5 ml/kg/min vs 31.3 ± 6.6; p = 0.03). Th erefore, VO2 peak 
shows a prognostic value in the monitoring of diastolic dysfunction of left  ventricle. 
According to the observation, NT-proBNP fails to identify patients whose LV 
function may deteriorate aft er 2 years. 
The outcomes of the study indicated a  high prognostic value of the exercise 
spiroergometric test in the identifi cation of patients, which allows to select of the 
individuals particularly susceptible to developing LV dysfunction. High prognostic 
value of VO2 peak in monitoring the development of LV diastolic function impairment 
was proved. 
According to the conducted research, stable angina pectoris is significantly 
related to the risk of developing left  ventricle diastolic dysfunction. Periodic control 
echocardiographic tests and spiroergometric test carried out despite lack of visible signs of 
heart failure, especially in type II diabetes patients, are vital in the detection of such risk.
Conclusions
Patients with stable angina pectoris and normal LV function are at risk of developing 
the impairment of heart function. Diastolic dysfunctions of left  ventricle are a crucial 
element of the whole clinical picture. Type II diabetes leads to left  ventricle diastolic 
dysfunction in a 2-year observation. 
According to own study and literature data, the predictors of LV diastolic function 
deterioration in a 2-year observation in this group of patients include type II diabetes 
and peak oxygen consumption VO2 peak.
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